Omeros Corporation (OMER) P/E Ratio History
ExpensiveTrading at 12.0x vs 5Y avg 3.6x · 100th percentile · Material premium to history · Data 2021–2026
Loading P/E history...
P/E Ratio Analysis
As of November 17, 2026, Omeros Corporation (OMER) trades at a price-to-earnings ratio of 12.0x, with a stock price of $16.68 and trailing twelve-month earnings per share of $1.39.
The current P/E is 229% above its 5-year average of 3.6x. Over the past five years, OMER's P/E has ranged from a low of 0.7x to a high of 9.3x, placing the current valuation at the 100th percentile of its historical range.
Compared to the Healthcare sector median P/E of 25.3x, OMER trades at a 53% discount to its sector peers. The sector includes 249 companies with P/E ratios ranging from 0.0x to 185.2x.
Relative to the broader market, OMER trades at a notable discount to the S&P 500 median P/E of 22.0x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our OMER DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
OMER Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
OMER P/E vs Peers
Commercial Immunology Biopharma peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $3B | 9.0 | - | +68% | |
| $11B | 24.4 | 1.06 | -25% | |
| $1B | 6.9Lowest | 0.67Best | +817%Best | |
| $16B | 405.6 | - | -1555% | |
| $44B | 31.7 | 0.78 | +5% | |
| $15B | 33.0 | - | -70% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
OMER Historical P/E Data (2021–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q2 | - | $9.51 | $1.72 | 5.5x | +52% |
| FY2026 Q1 | - | $10.56 | $1.14 | 9.3x | +154% |
| FY2023 Q3 | Sep 30 2023 | $2.92 | $0.32 | 9.1x | +151% |
| FY2023 Q2 | Jun 30 2023 | $5.44 | $1.45 | 3.8x | +3% |
| FY2023 Q1 | Mar 31 2023 | $4.65 | $2.15 | 2.2x | -41% |
| FY2022 Q4 | Dec 31 2022 | $2.26 | $2.09 | 1.1x | -70% |
| FY2022 Q3 | Sep 30 2022 | $3.15 | $4.52 | 0.7x | -81% |
| FY2022 Q2 | - | $2.75 | $3.63 | 0.8x | -79% |
| FY2022 Q1 | - | $6.01 | $3.06 | 2.0x | -46% |
| FY2021 Q4 | Dec 31 2021 | $6.43 | $3.09 | 2.1x | -43% |
Average P/E for displayed period: 3.6x
OMER Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
5+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
OMER — Frequently Asked Questions
Quick answers to the most common questions about buying OMER stock.
What is OMER's P/E ratio?
Omeros Corporation (OMER) trailing twelve-month P/E ratio is 12.0x, based on TTM diluted EPS of $1.39. The 5-year average P/E is 3.6x and the historical range spans 0.7x to 9.3x.
Is OMER stock overvalued or undervalued?
OMER trades at 12.0x P/E, above its 5-year average of 3.6x. The 100th percentile ranking within the 0.7x–9.3x historical range indicates a premium to historical valuation.
Is OMER stock expensive?
Yes, OMER is expensive relative to its own history. The current P/E of 12.0x is above the 5-year average of 3.6x. The stock sits at the 100th percentile of its 5-year valuation range.
What is OMER's historical P/E range?
Over the past 5 years, OMER's P/E ratio has ranged from 0.7x to 9.3x, with a median of 2.2x and an average of 3.6x. The current P/E of 12.0x places the stock at the 100th percentile of this range. Full historical data spans 2021–2026.
How does OMER's P/E compare to the S&P 500?
OMER trades at 12.0x P/E versus the S&P 500 median of 22.0x. The 45% discount to the market suggests lower growth expectations or perceived higher risk.
How does OMER's valuation compare to Healthcare peers?
Omeros Corporation P/E of 12.0x compares to the Healthcare sector median of 25.3x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is OMER's PEG ratio?
OMER PEG ratio is N/A, based on a P/E of 12.0x and EPS growth of 98.0%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is OMER's earnings yield?
OMER earnings yield is 8.35%, the inverse of its 12.0x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.